Highlights  CPP prevent cognitive dysfunction in APP/PS2 mouse model of Alzheimer's disease  CPP reduce hippocampal Aβ deposition  5-CQA, the main CPP component, degrades Aβ fibrils  CPP have a therapeutic potential for treating cognitive deficits in AD
Introduction
Alzheimer's disease (AD), a neurodegenerative disorder characterized by memory and cognitive dysfunction, is a public health problem worldwide. Its pathological features include the accumulation of amyloid β (Aβ) peptides (amyloid plaque) and aggregation of neurofibrillary tangles, which play causal and central roles in AD progression (Braak and Braak, 1997; Muke and Selkoe, 2012) . Aβ accumulation A C C E P T E D M A N U S C R I P T arises due to an imbalance between its synthesis and clearance. Aβ is generated by proteolytic processing that involves two types of proteases, namely, β-and γ-secretase (De Strooper et al., 2010) . A transmembrane aspartic protease called β-site APP cleaving enzyme (BACE1) is responsible for the β-secretase activity. Although BACE1 cleaves amyloid-β precursor protein (APP) and releases the soluble domain out of the cell, Aβ body remains attached to the C-terminal fragment (C99) bound to the cell membrane (Nathalie and Jean-Noël, 2008) . Furthermore, C99 undergoes cleavage by γ-secretase and releases Aβ isoforms such as Aβ 1-40 and Aβ 1-42 (Younkin, 1998) . Conversely, in the nonamyloidogenic pathway, α-secretase cleaves APP within the Aβ domain and produces soluble APP-α, thus preventing Aβ formation. Till date, no curative treatment for AD has been reported, and most therapeutic approaches transiently relieve symptoms but do not improve or inhibit disease progression. The dominantly inherited
Alzheimer's network study, which analyzes changes in the brain from pre-AD onset, revealed that AD develops as the brain changes over time (Bateman et al., 2012) . Hence, it has been speculated that treatments will be inefficient once the symptoms have emerged (Huang and Mucke, 2012) , which is why biomarker exploratory studies aiming for early diagnosis and prompt treatment (Suárez-Calvet et al., 2016) and prevention studies have attracted attention.
Coffee is a popular beverage worldwide and has been consumed since many years because of its attractive flavor and physiological effects. It is also one of the best documented food items with epidemiological effects (Arts and Hollman, 2005) .
Epidemiological studies found that coffee consumption habits may reduce the risk of mild cognitive impairment and AD (Panza et al., 2015; Solfrizzi et al., 2015) . Coffee contains numerous phenolic compounds [coffee polyphenols (CPP)], such as chlorogenic acids (CGAs), and a single cup of coffee contains 70-350 mg of CGAs Clifford, 1999) . Nakamura et al. demonstrated that the plasma concentrations of unmetabolized CGA peaked 0.5 h after the ingestion of coffee (CGAs = 300 mg) (Nakamura et al., 2006) , suggesting that the unmetabolized form of CGAs might exert its aforementioned protective effect. Several studies have reported that CGAs promote neuronal differentiation (Ito et al., 2008) and protect against A-induced cell death by disaggregating the A protein (Miyamae et al., 2012; Wei et al., 2016) . In addition,
CGAs possess antioxidant activity, thereby improving temporary amnesia in mice (Kwon et al., 2010) . A few clinical studies have reported the effects of CGAs on cognitive function. Acute administration of coffee enriched with CGAs to healthy elderly volunteers had a positive effect on mood and mood-related behavior. However, no improvement in cognitive function was reported (Cropley et al., 2011) . Similar results were obtained by Camfield et al. (Camfield et al., 2013) . However, recent studies have demonstrated that chronic (4-6-month) intake of CGAs improved cognitive function in the elderly (Kato et al., 2018; Saitou et al., 2018) . These findings led us to hypothesize that CGAs may prevent memory and cognitive dysfunction induced by Aβ.
However, whether CGAs have beneficial effects on AD is unknown. APP/PS2 mice are double transgenic mice that overexpress mutant forms of human Aβ precursor protein (hAPP) and human presenilin-2 (hPS2) (Richards et al., 2003; Toda et al., 2011) .
Richards et al. reported that APP/PS2 mice exhibit AD-like impairments, such as amyloidosis, inflammation, impaired synaptic plasticity, and cognitive dysfunction (Richards et al., 2003) .
In the present study, we used APP/PS2 mice as a model of AD to investigate whether the treatment with CPP may prevent/reduce progressive impairments in memory and cognitive function. These mice are a suitable model to investigate potential preventive and therapeutic strategies for AD because Aβ deposition is observed at 2-3
months of age. Thereafter, cognitive decline becomes apparent at 4-5 months of age (Toda et al., 2011) . These behavioral and pathological changes in APP/PS2 mice are due to age-related cognitive dysfunction associated with amyloidosis.
Materials and methods

Preparation of CPP
CPPs were extracted from Green coffee beans with hot water and spray dried.
The extract was mixed with 52.4% ethanol solution, acid clay (MIZUKA ACE #600;
Mizusawa Industrial Chemicals, Tokyo, Japan), and filter aid (SOLCA FLOC; JX Nippon Product Corporation, Tokyo, Japan) to obtain a CPP-containing slurry. The slurry was mixed with 52.4% ethanol solution and filtered with diatomaceous earth filter.
The filtrate was applied to activated charcoal column (SHIRASAGI WH2C; Osaka Gas Chemicals, Osaka, Japan) and cation-exchange resin column (SK1BH; Mitsubishi Chemical, Tokyo, Japan). The column processing solution was filtered using a 0.2 mm membrane filter, and ethanol was removed with a rotary evaporator. The CPP-rich fraction was diluted with distilled water to yield a 3% (w/v) solution and centrifuged at 15 °C (1000×g, 60 min). Thereafter, the precipitate was lyophilized to analyze the CPP composition by high-performance liquid chromatography. The total polyphenol content was 48.3%, and composed of various polyphenols as follows: 7.0% 3-caffeoylquinic acid (CQA), 7.5% 4-CQA, 17.8% 5-CQA, 1.3% 3-FQA, 1.5% 4-FQA, 3.9% 5-FQA, 3.4% 3,4-diCQA, 2.4% 3,5-diCQA, and 3.5% 4,5-diCQA. The CPP preparation contained no caffeine. The chemical structures of 5-CQA, 5-FQA, and 3,5-diCQA are shown in Fig. 1 .
Animal and diets
APP/PS2 double transgenic mice and wild-type (WT) littermates were generated as described by Toda et al. (Toda et al., 2011 Five-week-old male APP/PS2 mice and WT littermates were individually housed in a temperature-and humidity-controlled room (23 ± 3°C, 55 ± 15% relative humidity)
with an alternate 12 h light/dark cycle (lights on at 0600 h). The mice were divided into three groups (N = 12-15 mice/group). Behavioral analyses were performed on all mice (N=12-15 mice/group), and mice were divided into two populations on the basis of their behavioral analysis scores. One population was used for brain weight measurement and RNA extraction (N=6-8 mice/group). The other population was used for immunohistochemical analyses (N=6-7 mice/group). The mice were provided with ad libitum access to water and either control or CPP diet. The control diet consisted of 10%
(wt/wt) fat (corn oil), 20% casein, 61.5% potato starch, 4% cellulose, 3.5% vitamins, and 1% minerals. The CPP diet consisted of the control diet supplemented with 1% CPP; this amount was referred from a prior study (Murase et al., 2011) . Potato starch was reduced to 59.5% to compensate for the addition of CPP. Animals were maintained on these diets for 22 weeks. Individual body weights were recorded weekly, and food intake was measured every 3-4 days. Behavioral analyses were performed after 18
weeks. After 22 weeks, the mice were anesthetized using isoflurane (Forane®; Abbott, Tokyo, Japan) inhalation. The mice were then transcardially perfused with 20 ml of saline, followed by 20 ml of 4% paraformaldehyde (PFA; Wako Pure Chemical, Osaka, Japan). The perfusate was maintained at 4°C. After perfusion, the brain was dissected out, weighed, and stored in 4% PFA at 4°C until analysis. All animal experiments were conducted in the Experimental Animal Facility of the Kao Tochigi Institute in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The protocols were approved by the Kao Corporation Animal Care
Committee (Protocol Number: F15045-0000). All surgeries were performed under isoflurane anesthesia, and all efforts were made to minimize suffering.
Behavioral analyses
Behavioral analyses were performed after 18 weeks in the following order:
novel object recognition test, Morris water maze test, and step-through passive avoidance test.
Novel object recognition test
The novel object recognition test was performed in a plastic box (22 × 32 × 13 cm 3 ). In the habituation trial on the first day, the mice were allowed to explore the empty test box for 10 min. On the following day, two objects (blocks) were placed in the test box. During the training trial, each mouse was placed in the test box and allowed to explore the objects for 10 min. Mice were then returned to their home cage.
After a 2 h training trial, one of the two objects (familiar) was replaced by a new one (novel), and test trial was carried out for 5 min. All sessions were video recorded. The exploration time spent by a mouse touching the object with its nose was measured. Data 
Morris water maze test
The Morris water maze pool, which had a diameter of 148 cm, contained water (at 17-18 °C) with a platform (10 cm diameter) that was submerged 2 cm beneath the water surface. Mice were first trained (4 days, 3 sessions/day) to find the hidden platform. The platform location remained invariable during the training, however, the Step-through passive avoidance test
The step-through passive avoidance test chamber consisted of a light chamber (10 × 10 × 30 cm 3 ) and a dark chamber (24 × 24.5 × 30 cm 3 ), separated by a guillotine door (light and dark chamber; Nihon Bioresearch, Gifu, Japan). During the acquisition trial, each mouse was placed in the light chamber and allowed to explore freely. After 10 s, the guillotine door was opened, allowing the mouse access to the dark chamber.
The door closed after the mouse entered the dark chamber, and a 0.2 mA foot shock was
administered to the mouse for 3 s (Shock scrambler; UNICOM, Tokyo, Japan). The latency time for the mouse to enter the dark chamber was measured. Twenty-four hours after the acquisition trial, the mouse was placed in the light chamber for the test trial.
The time taken for a mouse to enter the dark chamber was recorded.
Immunohistochemistry
To detect Aβ plaques, brain samples were fixed in 4% PFA, embedded in paraffin, and 4-µm-thick sections were cut. Tissue sections were deparaffinized, treated with 90% formic acid for 5 min, and then, incubated with 0.1% hydrogen peroxide in methanol for 30 min to deactivate endogenous peroxidases. Subsequently, the tissue sections were incubated with the monoclonal anti-human Aβ antibody (#10323;
Immuno-Biological Laboratories, Gunma, Japan, 1:200) at 25 °C for 1 h. The tissue sections were then incubated with HRP-conjugated streptavidin (Nichirei Biosciences, Tokyo, Japan) for 5 min, and hydrogen peroxide as substrate and diaminobenzidine (DAKO, Tokyo, Japan) was used for color development. The images were acquired with a fluorescence microscope (BZ-X710; KEYENCE, Osaka, Japan), and quantitative image analysis was determined using BZ-II application (KEYENCE). Four slices from each mouse were used to quantify the mean average value of the selected regions. The
Aβ deposition in the cerebral cortex and dorsal hippocampus was analyzed as the percentage of brain regions covered by Aβ immunoreactivity.
RNA extraction and quantitative PCR (qPCR)
Total RNA was extracted using RNeasy Plus Universal Mini kit (Qiagen, Hiden, Germany). For real-time qPCR, cDNAs were synthesized with the High Capacity RNA-to-cDNA Kit (Applied Biosystems, Life Technologies, Forster City, CA, USA).
qPCR assays were performed using an Applied Biosystems ViiA7 Real-time PCR system (Applied Biosystems). Commercially available polymerase chain reaction primers and FAM-labeled TaqMan probes (TaqMan Gene Expression assays; Applied Biosystems) were used for the assays. The expression of each gene was normalized to that of the gene encoding GAPDH, a housekeeping gene. The genes assessed in this study are listed in Supplemental S1 Table. Aβ fibrillization assays 
Aβ disaggregation assays
Aβ1-42 peptides (Peptide Institute, Osaka, Japan) were dissolved in DMSO to 
Computational System
Aβ-5-CQA interaction was analyzed using Schrödinger Suite 2018-3 (URL:
https://www.schrodinger.com/suites/small-molecule-drug-discovery-suite). The 3D structures of Aβ were built from the nuclear magnetic resonance (NMR) structure of Aβ (residues 17-42) (Protein Data Bank ID: 2BEG), which has 10 models with five chains each (Lührs et al., 2005) . Protein Preparation Wizard was used to prepare the structures for all 10 models at pH 7.0. The N-termini were capped with the acetyl groups. The binding sites were analyzed for each model using Sitemap (URL:
https://www.schrodinger.com/sitemap). The initial 3-dimensional ligand structure was constructed using Ligprep at pH 7.0 ± 2.0. A docking study was performed using Glide 
Statistical analyses
Variables are expressed as the mean ± standard error of mean (SEM). Statistical analyses were conducted using one-way analysis of variance (ANOVA), followed by
Bonferroni's post-hoc test or T-test (GraphPad Prism 6; GraphPad Software, La Jolla,
CA, USA). Two-way repeated ANOVA, followed by Bonferroni's post-hoc test, was used to assess changes over time and between the groups (GraphPad Prism 6).
Differences were considered significant when P < 0.05. 
Effect of CPP on the performance of novel object recognition test
The effect of CPP on recognition memory was investigated using the novel object recognition test. In the training trial, the exploration time dedicated to the two objects was similar among the three groups (data not shown).
The test trial was carried out after a 2 h training trial. In the WT and APP/PS2 + CPP groups, the percentage of the time spent exploring the novel object was observed to increase (P < 0.001, Bonferroni's post-hoc test) as compared to that with the familiar object. However, the time dedicated exploring familiar versus novel objects did not significantly differ in the APP/PS2 group ( Fig. 2A) .
When the exploration time of the objects was analyzed as a function of the discrimination index, the APP/PS2 group showed a decrease (P < 0.001, Bonferroni's post-hoc test) compared with the WT group (Fig. 2B) . By contrast, the discrimination
index was increased in APP/PS2 mice treated with CPP (P < 0.001, Bonferroni's post-hoc test), indicating that the recognition memory improved in CPP-treated APP/PS2 mice (Fig. 2B) . The total exploration time during the test trial did not differ among the three groups (Fig. 2C) .
Effect of CPP on the performance of Morris water maze test
The effect of CPP on spatial learning and memory was investigated using the Morris water maze test. In the training trial, the escape latency time was significantly shorter (P < 0.05, Bonferroni's post-hoc test) in the WT group than in the APP/PS2 group (Fig. 3A) . The escape latency time did not differ significantly between the WT and APP/PS2+CPP groups (Fig. 3A) . The swimming speed was the same in the three groups (Fig. 3B) .
Following the 4-day training trial, test trials were performed on the fifth day.
The time swimming in the platform quadrant decreased (P < 0.01, Bonferroni's post-hoc test) in the APP/PS2 group compared with the WT group (Fig. 3C) , whereas it improved in the APP/PS2+CPP group compared with the APP/PS2 group (Fig. 3C ). The performance of the CPP-treated group was comparable to that of the WT group.
Effect of CPP on the performance of step-through passive avoidance test
The effect of CPP on long-term memory was investigated using the step-through passive avoidance test. In the acquisition trial, the latency time was similar in all groups (Fig. 4) . In the test trial, after the 24-hour acquisition trial, the latency time was found to be significantly longer (P < 0.05, Bonferroni's post-hoc test) in the WT group than in
the APP/PS2 group (Fig. 4) . The tendency for improvement in the latency time (P = 0.10, Bonferroni's post-hoc test) was observed in the APP/PS2 + CPP group compared to the APP/PS2 group (Fig. 4) .
Effect of CPP on Aβ deposition in the brain
The area occupied by Aβ plaques increased in the cortex and hippocampus of the APP/PS2 group compared with the WT group (Fig. 5A) , whereas it decreased in those of the APP/PS2 + CPP group compared with the APP/PS2 group (Fig. 5A ). The area of Aβ plaques in the hippocampus was significantly reduced (P < 0.05, T-test) in the APP/PS2 + CPP group compared with that in the APP/PS2 group (Fig. 5B ).
Effect of CPP on gene expression in the mouse brain
APP/PS2 mice showed significantly higher hippocampal and cortical mRNA expression of NOX2 and p22phox than the WT mice (Table. 1 
Effect of 5-CQA on Aβ formation
The fluorescence intensity of Aβ alone increased immediately and reached a plateau after 60 min of incubation. The presence of 5-CQA, the main component of CPP,
did not affect the fluorescence intensity, suggesting that 5-CQA did not inhibit Aβ fibrillization (Fig. 6A) .
Disaggregation of Aβ was observed with increasing dose of 5-CQA, and it reduced significantly (P < 0.05, Bonferroni's post-hoc test) following 5-CQA-supplementation (10 and 100 µM) (Fig. 6B ).
Interaction analysis of 5-CQA for Aβ protofilament
The eighth model of the NMR structure was used as it yielded the best 5-CQA-docking score. The docking study showed that 5-CQA interacted with the site around residues such as Phe19, Phe20, Ala21, Val36 and Gly38 (Fig. 7) .
In general, the effectiveness of coffee on health is due to the abundant polyphenols in coffee beans typified by CGAs. In this study, we found that chronic consumption of CPP improved memory and cognitive function and reduced Aβ pathology in APP/PS2 mice. Moreover, we demonstrated that CPP may modulate AD phenotypes by promoting disaggregation of fibrillar Aβ species into Aβ peptide in the brain.
The CPP-treated mice showed improvements in memory and cognitive function as assessed by three behavioral analyses. The novel object recognition test is based on the spontaneous tendency of rodents to explore novel objects without reward or penalty.
This test measures visual recognition memory and the spatial and temporal context of object recognition, supported by the interactions between the cortex and the hippocampus (Grayson et al., 2015) . The Morris water maze test investigates spatial learning and memory. This test involves the hippocampus, cerebral cortex, and striatum (D'Hooge and De Deyn, 2001 ). The step-through passive avoidance test evaluates long-term memory of learned avoidance behavior by electric foot shock. These behavioral analyses may reflect not only cognitive function, but also on motivation or motor function (Webster et al., 2013) . Improvements in the performance of learning and memory tasks in CPP-treated mice are unlikely to be due to the changes in activity, motivation, or motor function. The total object exploration time in the novel object recognition test, the swimming speed in the Morris water maze test, and the latency time during acquisition trial in the step-through passive avoidance test in CPP-treated mice did not differ from those in CPP-non-treated mice. These results suggest that exploratory activity and motor function, that is, the swimming ability, did not change.
Therefore, the improved behavioral performance in CPP-treated mice is probably due to CGAs exert an inhibitory effect on Aβ-protein aggregation (Miyamae et al., 2012) . Therefore, the influence of 5-CQA, a major component of CPP, on Aβ fibrils was investigated using the ThT assay. We observed disaggregation of Aβ fibrils, without an effect on Aβ fibril formation. Furthermore, the docking calculation analysis suggested that 5-CQA enters and interacts with a pocket structure of the Aβ protofibril model. The catechol of 5-CQA was found to be important for this interaction. Ciaramelli et al.
demonstrated that 5-CQAs are Aβ oligomer ligands and that their ability to inhibit fibrillation and neurotoxicity depends on their direct interaction with Aβ protofibrils (Ciaramelli et al., 2018.) . Curcumin, a substructure similar to 5-CQA, also features the ability to degrade Aβ: the catechol of curcumin interacts with the residue 12 and 17-21 of Aβ fibrils (Masuda et al., 2011) . Together with these previous findings, our docking calculation analysis and ThT assay indicate that 5-CQA promotes the disaggregation of fibril Aβ.
Ono et al. reported that wine polyphenols (myricetin, morin, quercetin,
kaempferol, (+)-catechin and (−)-epicatechin), curcumin, rosmarinic acid, and grape seed-derived polyphenols with phenolic groups like CGA disaggregate and destabilize the Aβ fibrils and reduce its cytotoxicity (Ono et al., 2003; Ono et al., 2004; Ono et al., 2008) . Wei et al. reported that CGA has a neuroprotective effect on the cytotoxicity of Aβ (Wei et al., 2016) . These studies suggest that CGA may disaggregate Aβ fibrils and could possibly reduce cytotoxicity. Conventionally, Aβ fibrils that accumulate as cerebral amyloid are thought to exert neurotoxicity. However, in recent years, oligomers, the intermediate stages of amyloid β protein aggregation, have been reported to be the most toxic, and oligomer reduction was suggested as effective for treating AD (Ono et al., 2009) . Additionally, it has been reported that polyphenols block Aβ oligomerization and reduce the cellular toxicity and synaptic dysfunction of the Aβ oligomers Ono et al., 2012; Wang et al., 2014) . We measured Aβ oligomer levels in the mice hippocampus using an immuno-assay and found them to have significantly increased in the APP/PS2 group relative to the WT group; however, they did not differ between the APP/PS2+CPP and APP/PS2 groups (data not shown). aggregates (Ho et al., 2009) . It is important to consider the pharmacokinetics of polyphenols, including its blood-brain barrier (BBB) permeability for polyphenols to be effective in the brain. For example, the polyphenol proanthocyanidin constitutes monomeric, oligomeric, and polymeric forms, and the monomeric metabolites have been reported to selectively reach and accumulate in the brain and exert their effects (Wang et al., 2012) . However, the present study was unable to reveal the differential effects of CPP and other polyphenols on Aβ or tau, and their pharmacokinetics including BBB permeability. Thus, the mechanism underlying CPP action should also be explored by future research.
Transthyretin has been shown to interact with Aβ peptides and suppress Aβ-oligomer toxicity (Buxbaum et al., 2008.) . Further, serum concentrations of transthyretin reportedly decrease as AD progresses (Uchida et al., 2015.) . Hop-derived components that prevent cognitive impairment of AD-model mice increase the expression of transthyretin in the hippocampus (Fukuda et al., 2018.) . CPP may have decreased the toxicity of Aβ by increasing the expression of transthyretin, possibly helping to prevent cognitive impairment thereby.
Aβ deposition is observed in APP/PS2 mice from 2 to 3 months of age and it increases with time; cognitive function decreases after 4-5 months of age (Richards et al., 2003; Toda et al., 2011) . Fontana et al. reported that synaptic excitability of the hippocampus changes from 3 months of age in APP/PS2 mice (Fontana et al., 2017) . In addition, the increase in Aβ deposition in humans begins 15-20 years before AD onset (Bateman et al., 2012) . Therefore, it is important to protect the brain from disorders
caused by Aβ and prevent the onset of AD through early intervention. The clearance of Aβ in the brain was insufficient to improve cognitive dysfunction in AD (Salloway et al., 2014) . In this study, CGA was given to 5-week-old mice before the changes in Aβ deposition, cognitive function, and synaptic function occurred, and therefore, the preventive effect of CGA on AD onset was clearly demonstrated. Further studies are needed to precisely analyze the mechanism underlying the effect of CGA on brain functions and its effectiveness on existing Aβ deposits and cognitive decline. CGA not only reduces Aβ deposition, but also alleviates the inhibitory actions on antioxidant and AChE activity (Kwon et al., 2010) . Thus, these findings suggest that CGA can improve cognitive dysfunction through several pathways and may exert a therapeutic effect in AD.
Conclusion
We demonstrated that CPP treatment significantly attenuated impairments in the decline of recognition and spatial memory in a mouse model of AD. The reduction of Aβ plaque deposition in the hippocampus may account for these findings. Consequently, CPP provided a protective effect against AD progression through Aβ in mice. These findings strongly suggest CPP as an effective therapeutic and prophylactic agent for cognitive deficits in AD.
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